MedTrace Logo

Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice

NCT03722836 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 708

Last updated 2023-01-13

Study results available
· View outcomes & findings →

Summary

The VAP-PRO-C3 is a multicenter observational program, which is carried out in the frame of routine consultations and follow-up of patients. The program includes patients with chronic venous diseases (CVDs) of CEAP class C3. It is scheduled in Russia for 2018-2019. The program is expected to enroll 90 phlebologists from 60 cities of Russia. The planned number of patients is 900

Conditions

  • Chronic Venous Disease

Sponsors & Collaborators

  • Servier Russia

    lead INDUSTRY

Principal Investigators

  • Yuriy Stoyko

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-06
Primary Completion
2019-06-15
Completion
2019-06-20

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03722836 on ClinicalTrials.gov